Format

Send to

Choose Destination
Eur J Cancer. 2016 May;59:79-89. doi: 10.1016/j.ejca.2016.02.006. Epub 2016 Mar 24.

Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01).

Author information

1
Gustave Roussy, Département de Radiologie interventionnelle, France. Electronic address: vaniatacher@gmail.com.
2
INSERM, CESP Equipe 2, France; Gustave Roussy, Service de Biostatistique et d'Epidémiologie, Université Paris-Sud, UFR de Médecine, France. Electronic address: Marie-Cecile.LEDELEY@gustaveroussy.fr.
3
Gustave Roussy, Département d'Innovation Thérapeutique et d'Essais Précoces, France. Electronic address: Antoine.HOLLEBECQUE@gustaveroussy.fr.
4
Gustave Roussy, Département de Radiologie interventionnelle, France. Electronic address: Frederic.DESCHAMPS@gustaveroussy.fr.
5
Gustave Roussy, Département d'Anatomopathologie, France. Electronic address: Philippe.VIELH@gustaveroussy.fr.
6
Gustave Roussy, Département de Radiologie interventionnelle, France. Electronic address: thakime@yahoo.com.
7
Gustave Roussy, Département d'Innovation Thérapeutique et d'Essais Précoces, France. Electronic address: Elena.ILEANAECATERINA@gustaveroussy.fr.
8
Gustave Roussy, Département d'Anatomopathologie, France. Electronic address: BEHNOUSH.ABEDI@gustaveroussy.fr.
9
Gustave Roussy, Département d'Anatomopathologie, France. Electronic address: Cecile.CHARPY@gustaveroussy.fr.
10
Gustave Roussy, Département d'Innovation Thérapeutique et d'Essais Précoces, France. Electronic address: Christophe.MASSARD@gustaveroussy.fr.
11
Gustave Roussy, Service de Biostatistique et d'Epidémiologie, Université Paris-Sud, UFR de Médecine, France. Electronic address: SILVIA.ROSELLINI@gustaveroussy.fr.
12
Gustave Roussy, Service de Biostatistique et d'Epidémiologie, Université Paris-Sud, UFR de Médecine, France. Electronic address: dorota_gajda@yahoo.fr.
13
Gustave Roussy, Service de Biostatistique et d'Epidémiologie, Université Paris-Sud, UFR de Médecine, France. Electronic address: Aljosa.CELEBIC@gustaveroussy.fr.
14
Gustave Roussy, Département of Medical Oncology, France. Electronic address: Charles.FERTE@gustaveroussy.fr.
15
Gustave Roussy, Département d'Innovation Thérapeutique et d'Essais Précoces, France. Electronic address: Maud.NGOCAMUS@gustaveroussy.fr.
16
Gustave Roussy, Service de Biostatistique et d'Epidémiologie, Université Paris-Sud, UFR de Médecine, France. Electronic address: SIHAM.GOUISSEM@gustaveroussy.fr.
17
Gustave Roussy, Laboratoire de Recherche Translationnelle, France. Electronic address: Valerie.KOUBI-PICK@gustaveroussy.fr.
18
Gustave Roussy, Département of Medical Oncology, France; Université Paris-Sud, UFR Médicale Le Kremlin-Bicêtre, France. Electronic address: Fabrice.ANDRE@gustaveroussy.fr.
19
Université Paris-Sud, UFR Médicale Le Kremlin-Bicêtre, France; Gustave Roussy, Direction de la Recherche Clinique, France. Electronic address: Gilles.Vassal@gustaveroussy.fr.
20
Gustave Roussy, Département de Médecine Nucléaire, France. Electronic address: Desiree.DEANDREIS@gustaveroussy.fr.
21
Gustave Roussy, Laboratoire de Recherche Translationnelle, France; Université Paris-Sud, UFR Médicale Le Kremlin-Bicêtre, France. Electronic address: Ludovic.LACROIX@gustaveroussy.fr.
22
Gustave Roussy, Département d'Innovation Thérapeutique et d'Essais Précoces, France; Université Paris-Sud, UFR Médicale Le Kremlin-Bicêtre, France. Electronic address: Jean-Charles.Soria@gustaveroussy.fr.
23
Gustave Roussy, Département de Radiologie interventionnelle, France; Université Paris-Sud, UFR Médicale Le Kremlin-Bicêtre, France. Electronic address: Thierry.DEBAERE@gustaveroussy.fr.

Abstract

INTRODUCTION:

MOSCATO-01 is a molecular triage trial based on on-purpose tumour biopsies to perform molecular portraits. We aimed at identifying factors associated with high tumour cellularity.

MATERIAL AND METHODS:

Tumour cellularity (percentage of tumour cells in samples defined at pathology) was evaluated according to patient characteristics, target lesion characteristics, operators' experience and biopsy approach.

RESULTS:

Among 460 patients enrolled between November, 2011 and March, 2014, 334 patients (73%) had an image-guided needle biopsy of the primary tumour (N = 38) or a metastatic lesion (N = 296). Biopsies were performed on liver (N = 127), lung (N = 72), lymph nodes (N = 71), bone (N = 11), or another tumour site (N = 53). Eighteen patients (5%) experienced a complication: pneumothorax in 10 patients treated medically, and haemorrhage in 8, requiring embolisation in 3 cases. Median tumour cellularity was 50% (interquartile range, 30-70%). The molecular analysis was successful in 291/334 cases (87%). On-going chemotherapy, tumour origin (primary versus metastatic), lesion size, tumour growth rate, presence of necrosis on imaging, standardised uptake value, and needle size were not statistically associated with cellularity. Compared to liver or lung biopsies, cellularity was significantly lower in bone and higher in other sites (P < 0.0001). Cellularity significantly increased with the number of collected samples (P < 0.0001) and was higher in contrast-enhanced ultrasound-guided biopsies (P < 0.02). In paired samples, cellularity in central samples was lower than in peripheral samples in 85, equal in 68 and higher in 89 of the cases.

CONCLUSION:

Image-guided biopsy is feasible and safe in cancer patients for molecular screening. Imaging modality, multiple sampling of the lesion, and the organ chosen for biopsy were associated with higher tumour cellularity.

KEYWORDS:

Image-guided tumour biopsies; Molecular triage

PMID:
27017289
DOI:
10.1016/j.ejca.2016.02.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center